Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/31/2024 | $20.00 | Overweight | Wells Fargo |
9/6/2024 | $20.00 | Buy | Stifel |
2/23/2024 | Overweight | Cantor Fitzgerald | |
9/22/2023 | $8.00 | Outperform | Wedbush |
3/23/2023 | $16.00 | Neutral → Buy | H.C. Wainwright |
3/21/2023 | $15.00 | Neutral → Buy | Guggenheim |
3/16/2023 | $14.00 | Perform → Outperform | Oppenheimer |
7/18/2022 | Perform | Oppenheimer |
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 1, 2024 (the "Grant Date"), ORIC granted a total of 61,800 non-qualified stock options and 10,400 restricted stock units to two new non-executive employees who began their employment with ORIC in October 2024. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The s
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the company presented a poster highlighting certain best-in-class properties of ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. "Preclinical data presented today underscore ORIC-114's superior potency and selectively across EGFR mutational classes compared to other EG
Candid Therapeutics, Inc. ("Candid"), a clinical stage biotechnology company positioned to lead the development of T-cell engagers for autoimmune diseases, appointed repeatedly successful industry veterans, Angie You, Ph.D. and Dan Puckett, to its board of directors. "T-cell engagers have the potential to tranform the treatment of many autoimmune diseases. Ken has assembled a world-class management team and an diverse portfolio of assets. I am excited to partner with him, the Candid board and management team to support the company in it's ambitious growth plans," said Dr. You. "Ken and team have made tremendous progress in a very short timeframe. I believe Candid is well positioned to be
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
Wells Fargo initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
Stifel initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Cantor Fitzgerald initiated coverage of ORIC Pharmaceuticals with a rating of Overweight
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price target.
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $21 price target.
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
10-Q - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
SAN FRANCISCO, Sept. 17, 2024 /PRNewswire/ -- OpenBench, Inc., a pioneer in AI-enabled success-driven small molecule discovery partnerships, today announced the launch of a collaboration with ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. The parties aim to apply OpenBench's success-driven discovery approach and structure-based machine learning platform to enrich early discovery efforts against an undisclosed target identified by ORIC's resistance platform to target cancer-specific vulnerabilities.
Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combination with NUBEQA® and in combination with ERLEADA® Expanded leadership team with the appointment of industry veteran Keith Lui as Senior Vice President of Commercial and Medical Affairs Cash and investments of $308.5 million expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals,
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs. "We are thrilled to welcome Keith to the ORIC leadership team," said Jacob M. Chacko, M.D., president and chief executive officer. "Keith's exceptional multi-decade track record of helping to bring innovative therapies to market, combined with his experience in strategic planning and medical affairs, will be invaluable as we advance our differentiated p
Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response Responses observed at multiple dose levels in HER2 exon 20 patients, including a partial response with 100% target lesion
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20-24, 2023, in Madrid, Spain. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. In conjunction with the ESMO presentations, OR